LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Akciju saraksts・Innoviva Inc

Innoviva Inc

Slēgts

SektorsVeselības aprūpe

22.81 0.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

22.47

Max

23.07

Galvenie mērījumi
By Trading Economics
Ienākumi	152M 242M
Pārdošana	10M 118M
P/E Sektora vidējais	7.009 49.8
Peļņas marža	204.74
Darbinieki	159
EBITDA	100M 208M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+51.75% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	43M 1.7B
Iepriekšējā atvēršanas cena	22.77
Iepriekšējā slēgšanas cena	22.81

Ziņu noskaņojums

By Acuity

14%

86%

27 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

18.57 / 18.75 Atbalsts un pretestība

Innoviva Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. maijs 23:55 UTC

Peļņas

Review & Preview: Still Going Strong -- Barrons.com

2026. g. 8. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 20:49 UTC

Peļņas

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026. g. 8. maijs 20:25 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Net $115M

2026. g. 8. maijs 19:20 UTC

Tirgus saruna

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026. g. 8. maijs 19:18 UTC

Peļņas

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026. g. 8. maijs 19:16 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:08 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:05 UTC

Peļņas

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026. g. 8. maijs 19:02 UTC

Tirgus saruna

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026. g. 8. maijs 18:51 UTC

Peļņas

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026. g. 8. maijs 18:49 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 18:41 UTC

Peļņas

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026. g. 8. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026. g. 8. maijs 17:14 UTC

Peļņas

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026. g. 8. maijs 17:04 UTC

Tirgus saruna

Zcash Caps Off Parabolic Week -- Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Canada's Job Market Sees Worst Start in Years -- Market Talk

2026. g. 8. maijs 15:36 UTC

Tirgus saruna

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

'Altcoin Season' Indicator on the Rise -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

Peļņas

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

2026. g. 8. maijs 15:05 UTC

Tirgus saruna

Bitcoin Slips Back Below the $80k Mark -- Market Talk

2026. g. 8. maijs 14:42 UTC

Tirgus saruna

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

2026. g. 8. maijs 14:39 UTC

Tirgus saruna

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Salīdzinājums

Cenas izmaiņa

Innoviva Inc Prognoze

Cenas mērķis

By TipRanks

51.75% augšup

Prognoze 12 mēnešiem

Vidējais 34.6 USD 51.75%

Augstākais 46 USD

Zemākais 18 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Innoviva Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Innoviva Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

18.57 / 18.75Atbalsts un pretestība

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

27 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.